行情

ITCI

ITCI

INTRA CELLULAR
NASDAQ

实时行情|Nasdaq Last Sale

8.54
-0.20
-2.29%
盘后: 9.00 +0.46 +5.39% 17:42 09/20 EDT
开盘
8.76
昨收
8.74
最高
8.80
最低
8.28
成交量
193.54万
成交额
--
52周最高
23.62
52周最低
7.41
市值
4.71亿
市盈率(TTM)
-3.0345
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ITCI 新闻

  • 德国银行业协会预计该国GDP增长率为0.5%
  • 新浪美股.2小时前
  • 特朗普呼吁将利率降至零以下:我们应比别人少付利息
  • 新浪美股.3小时前
  • 网易“潜伏”海外:攻占日韩 “出师”印度 远征非洲
  • 新浪美股.3小时前
  • 股价迄今飙升超300% Roku投资者为何急跳墙?
  • 新浪财经-自媒体综合.4小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

ITCI 简况

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
展开

Webull提供Intra-Cellular Therapies Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。